10-Q Filing

INSIGHT MOLECULAR DIAGNOSTICS INC. CIK: 1642380 Q2 2021

Filing Information

Form Type	10-Q
Accession Number	`0001493152-21-019327`
Period End Date	20210630
Filing Date	20210811
Fiscal Year	2021
Fiscal Period	Q2
XBRL Instance	form10-q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 82 Income Statement 84 Cash Flow Statement 114 Stockholders Equity 37

Balance Sheet 82 line items

Line Item	Tag	Value	Unit	Period
Preferred stock no par value	`PreferredStockNoParValue`	-	USD	Point-in-time
Preferred stock no par value	`PreferredStockNoParValue`	-	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$46.47M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$7.14M	USD	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$1.02M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$203.00K	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Marketable equity securities	`EquitySecuritiesFvNi`	$675.00K	USD	Point-in-time
Marketable equity securities	`EquitySecuritiesFvNi`	$1.06M	USD	Point-in-time
Common stock, no par value	`CommonStockNoParValue`	-	USD	Point-in-time
Common stock, no par value	`CommonStockNoParValue`	-	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.21M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.44M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	230.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	230.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$9.23M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$49.99M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	69.12M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	90.32M	shares	Point-in-time
Common stock, shares, outstanding	`CommonStockSharesOutstanding`	69.12M	shares	Point-in-time
Common stock, shares, outstanding	`CommonStockSharesOutstanding`	90.32M	shares	Point-in-time
Right-of-use and financing lease assets, net	`FinanceLeaseRightOfUseAsset`	$3.26M	USD	Point-in-time
Right-of-use and financing lease assets, net	`FinanceLeaseRightOfUseAsset`	$2.95M	USD	Point-in-time
Machinery and equipment, net, and construction in progress	`MachineryAndEquipmentNetAndConstructionInProgress`	$3.26M	USD	Point-in-time
Machinery and equipment, net, and construction in progress	`MachineryAndEquipmentNetAndConstructionInProgress`	$4.40M	USD	Point-in-time
Equity method investment in Razor	`EquityMethodInvestments`	-	USD	Point-in-time
Equity method investment in Razor	`EquityMethodInvestments`	$13.42M	USD	Point-in-time
Goodwill	`Goodwill`	$15.04M	USD	Point-in-time
Goodwill	`Goodwill`	$24.24M	USD	Point-in-time
Goodwill	`Goodwill`	$9.19M	USD	Point-in-time
Goodwill	`Goodwill`	$9.19M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$15.01M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$93.71M	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$1.70M	USD	Point-in-time
Restricted cash	`RestrictedCashNoncurrent`	$1.70M	USD	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$393.00K	USD	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$356.00K	USD	Point-in-time
TOTAL ASSETS	`Assets`	$177.38M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$55.42M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$432.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$1.09M	USD	Point-in-time
Accrued compensation	`AccruedLiabilitiesCurrent`	$3.47M	USD	Point-in-time
Accrued compensation	`AccruedLiabilitiesCurrent`	$2.78M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$1.93M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$2.28M	USD	Point-in-time
Accrued liabilities from acquisition, current	`BusinessCombinationContingentConsiderationLiabilityCurrent`	$11.73M	USD	Point-in-time
Accrued liabilities from acquisition, current	`BusinessCombinationContingentConsiderationLiabilityCurrent`	-	USD	Point-in-time
Loans payable, current	`LoansPayableCurrent`	$2.39M	USD	Point-in-time
Loans payable, current	`LoansPayableCurrent`	$1.50M	USD	Point-in-time
Right-of-use and financing lease liabilities, current	`OperatingLeaseAndFinancingLeaseLiabilitiesCurrent`	$422.00K	USD	Point-in-time
Right-of-use and financing lease liabilities, current	`OperatingLeaseAndFinancingLeaseLiabilitiesCurrent`	$737.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$9.00M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$19.77M	USD	Point-in-time
Loans payable, net of deferred financing costs, noncurrent	`LongTermLoansPayable`	$1.51M	USD	Point-in-time
Loans payable, net of deferred financing costs, noncurrent	`LongTermLoansPayable`	$541.00K	USD	Point-in-time
Right-of-use and financing lease liabilities, noncurrent	`OperatingLeaseLiabilitiesAndFinancingLeaseLiabilitiesNonCurrent`	$4.31M	USD	Point-in-time
Right-of-use and financing lease liabilities, noncurrent	`OperatingLeaseLiabilitiesAndFinancingLeaseLiabilitiesNonCurrent`	$3.90M	USD	Point-in-time
Contingent consideration liabilities, noncurrent	`BusinessCombinationContingentConsiderationLiabilityNoncurrent`	$7.12M	USD	Point-in-time
Contingent consideration liabilities, noncurrent	`BusinessCombinationContingentConsiderationLiabilityNoncurrent`	$50.51M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$21.94M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$74.72M	USD	Point-in-time
Commitments and contingencies (Note 10)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 10)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, no par value, 230,000 shares authorized; 90,316 and 69,117 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	`CommonStockValue`	$240.75M	USD	Point-in-time
Common stock, no par value, 230,000 shares authorized; 90,316 and 69,117 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	`CommonStockValue`	$157.16M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-123.68M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-138.09M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$30.84M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$36.62M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$102.67M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$33.48M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$106.63M	USD	Point-in-time
Total shareholders equity	`StockholdersEquity`	$39.59M	USD	Point-in-time
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$177.38M	USD	Point-in-time
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$55.42M	USD	Point-in-time

Income Statement 84 line items

Line Item	Tag	Value	Unit	Period
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$2.03M	USD	1 Quarter
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$3.15M	USD	2 Qtrs
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$143.00K	USD	1 Quarter
Net revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$158.00K	USD	2 Qtrs
Cost of revenues	`CostOfRevenue`	$365.00K	USD	1 Quarter
Cost of revenues	`CostOfRevenue`	$1.35M	USD	1 Quarter
Cost of revenues	`CostOfRevenue`	$538.00K	USD	2 Qtrs
Cost of revenues	`CostOfRevenue`	$2.09M	USD	2 Qtrs
Cost of revenues amortization of acquired intangibles	`CostOfRevenuesAmortizationOfAcquiredIntangibles`	-	USD	2 Qtrs
Cost of revenues amortization of acquired intangibles	`CostOfRevenuesAmortizationOfAcquiredIntangibles`	$1.38M	USD	2 Qtrs
Cost of revenues amortization of acquired intangibles	`CostOfRevenuesAmortizationOfAcquiredIntangibles`	-	USD	1 Quarter
Cost of revenues amortization of acquired intangibles	`CostOfRevenuesAmortizationOfAcquiredIntangibles`	$1.07M	USD	1 Quarter
Gross profit	`GrossProfit`	$-222.00K	USD	1 Quarter
Gross profit	`GrossProfit`	$-380.00K	USD	2 Qtrs
Gross profit	`GrossProfit`	$-315.00K	USD	2 Qtrs
Gross profit	`GrossProfit`	$-394.00K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$2.54M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$5.90M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$5.38M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$3.23M	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$4.93M	USD	2 Qtrs
Sales and marketing	`SellingAndMarketingExpense`	$2.67M	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$1.56M	USD	1 Quarter
Sales and marketing	`SellingAndMarketingExpense`	$3.05M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$3.76M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$12.70M	USD	2 Qtrs
General and administrative	`GeneralAndAdministrativeExpense`	$7.93M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$8.38M	USD	2 Qtrs
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$1.09M	USD	2 Qtrs
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	-	USD	2 Qtrs
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	-	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$30.00K	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$13.17M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$24.61M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$16.82M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$8.55M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-8.77M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-13.57M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-24.93M	USD	2 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-17.20M	USD	2 Qtrs
Interest expense, net	`InterestIncomeExpenseNet`	$-75.00K	USD	1 Quarter
Interest expense, net	`InterestIncomeExpenseNet`	$-49.00K	USD	1 Quarter
Interest expense, net	`InterestIncomeExpenseNet`	$-117.00K	USD	2 Qtrs
Interest expense, net	`InterestIncomeExpenseNet`	$-97.00K	USD	2 Qtrs
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$173.00K	USD	1 Quarter
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$386.00K	USD	2 Qtrs
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-38.00K	USD	2 Qtrs
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$16.00K	USD	1 Quarter
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-270.00K	USD	2 Qtrs
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	-	USD	1 Quarter
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-301.00K	USD	1 Quarter
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-630.00K	USD	2 Qtrs
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	$1.14M	USD	2 Qtrs
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	-	USD	2 Qtrs
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	-	USD	1 Quarter
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	$1.14M	USD	1 Quarter
Other income, net	`OtherNonoperatingIncomeExpense`	$30.00K	USD	2 Qtrs
Other income, net	`OtherNonoperatingIncomeExpense`	$16.00K	USD	1 Quarter
Other income, net	`OtherNonoperatingIncomeExpense`	$20.00K	USD	1 Quarter
Other income, net	`OtherNonoperatingIncomeExpense`	$18.00K	USD	2 Qtrs
Total other expenses, net	`NonoperatingIncomeExpense`	$1.28M	USD	1 Quarter
Total other expenses, net	`NonoperatingIncomeExpense`	$1.16M	USD	2 Qtrs
Total other expenses, net	`NonoperatingIncomeExpense`	$-735.00K	USD	2 Qtrs
Total other expenses, net	`NonoperatingIncomeExpense`	$-340.00K	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-9.11M	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-12.29M	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-23.77M	USD	2 Qtrs
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-17.93M	USD	2 Qtrs
Income tax benefit	`IncomeTaxExpenseBenefit`	-	USD	1 Quarter
Income tax benefit	`IncomeTaxExpenseBenefit`	$-9.36M	USD	2 Qtrs
Income tax benefit	`IncomeTaxExpenseBenefit`	$-1.09M	USD	2 Qtrs
Income tax benefit	`IncomeTaxExpenseBenefit`	$-1.79M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-16.84M	USD	2 Qtrs
NET LOSS	`NetIncomeLoss`	$-10.49M	USD	1 Quarter
NET LOSS	`NetIncomeLoss`	$-14.41M	USD	2 Qtrs
NET LOSS	`NetIncomeLoss`	$-9.11M	USD	1 Quarter
Net loss per share: basic and diluted	`EarningsPerShareBasicAndDiluted`	$0.26	USD	2 Qtrs
Net loss per share: basic and diluted	`EarningsPerShareBasicAndDiluted`	$0.12	USD	1 Quarter
Net loss per share: basic and diluted	`EarningsPerShareBasicAndDiluted`	$0.14	USD	1 Quarter
Net loss per share: basic and diluted	`EarningsPerShareBasicAndDiluted`	$0.17	USD	2 Qtrs
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	63.63M	shares	2 Qtrs
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	89.76M	shares	1 Quarter
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	65.83M	shares	1 Quarter
Weighted average shares outstanding: basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	85.96M	shares	2 Qtrs

Cash Flow Statement 114 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-16.84M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-10.49M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-14.41M	USD	2 Qtrs
Net loss	`NetIncomeLoss`	$-9.11M	USD	1 Quarter
Depreciation expense	`Depreciation`	$67.00K	USD	1 Quarter
Depreciation expense	`Depreciation`	$327.00K	USD	2 Qtrs
Depreciation expense	`Depreciation`	$206.00K	USD	1 Quarter
Depreciation expense	`Depreciation`	$127.00K	USD	2 Qtrs
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$37.00K	USD	2 Qtrs
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$1.38M	USD	2 Qtrs
Amortization of right-of-use assets and liabilities	`AmortizationOfRightOfUseAssetsAndLiabilities`	$301.00K	USD	2 Qtrs
Amortization of right-of-use assets and liabilities	`AmortizationOfRightOfUseAssetsAndLiabilities`	$218.00K	USD	2 Qtrs
Impairment charge for long-lived assets	`ImpairmentOfLongLivedAssetsToBeDisposedOf`	-	USD	2 Qtrs
Impairment charge for long-lived assets	`ImpairmentOfLongLivedAssetsToBeDisposedOf`	$422.00K	USD	2 Qtrs
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-270.00K	USD	2 Qtrs
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	-	USD	1 Quarter
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-301.00K	USD	1 Quarter
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-630.00K	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$2.30M	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$2.00M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$3.29M	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$1.36M	USD	1 Quarter
Unrealized (gain) loss on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$173.00K	USD	1 Quarter
Unrealized (gain) loss on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$386.00K	USD	2 Qtrs
Unrealized (gain) loss on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-38.00K	USD	2 Qtrs
Unrealized (gain) loss on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$16.00K	USD	1 Quarter
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$33.00K	USD	2 Qtrs
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$57.00K	USD	2 Qtrs
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$1.09M	USD	2 Qtrs
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	-	USD	2 Qtrs
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	-	USD	1 Quarter
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$30.00K	USD	1 Quarter
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	$-1.09M	USD	2 Qtrs
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	$-9.36M	USD	2 Qtrs
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	$1.14M	USD	2 Qtrs
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	-	USD	2 Qtrs
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	-	USD	1 Quarter
Gain on extinguishment of debt (PPP loan)	`GainsLossesOnExtinguishmentOfDebt`	$1.14M	USD	1 Quarter
Accrued severance from Chronix Biomedical acquisition	`AccruedSeveranceFromChronixBiomedicalAcquisition`	-	USD	2 Qtrs
Accrued severance from Chronix Biomedical acquisition	`AccruedSeveranceFromChronixBiomedicalAcquisition`	$2.45M	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$817.00K	USD	2 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$85.00K	USD	2 Qtrs
Amount due to Lineage and affiliates	`IncreaseDecreaseInDueToRelatedParties`	-	USD	2 Qtrs
Amount due to Lineage and affiliates	`IncreaseDecreaseInDueToRelatedParties`	$-6.00K	USD	2 Qtrs
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$779.00K	USD	2 Qtrs
Prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$103.00K	USD	2 Qtrs
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$1.06M	USD	2 Qtrs
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-766.00K	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-17.93M	USD	2 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-13.83M	USD	2 Qtrs
Acquisition of Insight Genetics, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$607.00K	USD	2 Qtrs
Acquisition of Insight Genetics, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$6.19M	USD	2 Qtrs
Acquisition of Razor Genomics asset, net of cash acquired	`AcquisitionOfRazorGenomicsAssetNetOfCashAcquired`	-	USD	2 Qtrs
Acquisition of Razor Genomics asset, net of cash acquired	`AcquisitionOfRazorGenomicsAssetNetOfCashAcquired`	$6.65M	USD	2 Qtrs
Acquisition of Chronix Biomedical, net of cash acquired	`AcquisitionOfChronixBiomedicalNetOfCashAcquired`	$4.46M	USD	2 Qtrs
Acquisition of Chronix Biomedical, net of cash acquired	`AcquisitionOfChronixBiomedicalNetOfCashAcquired`	-	USD	2 Qtrs
Equity method investment in Razor	`PaymentsToAcquireEquityMethodInvestments`	$4.00M	USD	2 Qtrs
Equity method investment in Razor	`PaymentsToAcquireEquityMethodInvestments`	-	USD	2 Qtrs
Construction in progress and purchases of furniture and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$535.00K	USD	2 Qtrs
Construction in progress and purchases of furniture and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.45M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-13.17M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-10.72M	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$1.60M	USD	2 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	-	USD	2 Qtrs
Proceeds from sale of common shares	`ProceedsFromIssuanceOfCommonStock`	$65.26M	USD	2 Qtrs
Proceeds from sale of common shares	`ProceedsFromIssuanceOfCommonStock`	$18.34M	USD	2 Qtrs
Financing costs to issue common shares	`PaymentsOfStockIssuanceCosts`	$2.68M	USD	2 Qtrs
Financing costs to issue common shares	`PaymentsOfStockIssuanceCosts`	$31.00K	USD	2 Qtrs
Proceeds from sale of common shares under at-the-market transactions	`ProceedsFromIssuanceOfPrivatePlacement`	$6.48M	USD	2 Qtrs
Proceeds from sale of common shares under at-the-market transactions	`ProceedsFromIssuanceOfPrivatePlacement`	-	USD	2 Qtrs
Financing costs for at-the-market sales	`PaymentForFinancingCostsForAtthemarketSales`	-	USD	2 Qtrs
Financing costs for at-the-market sales	`PaymentForFinancingCostsForAtthemarketSales`	$203.00K	USD	2 Qtrs
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	-	USD	2 Qtrs
Proceeds from exercise of warrants	`ProceedsFromWarrantExercises`	$823.00K	USD	2 Qtrs
Common shares received and retired for employee taxes paid	`CommonSharesReceivedAndRetiredForEmployeeTaxesPaid`	$37.00K	USD	2 Qtrs
Common shares received and retired for employee taxes paid	`CommonSharesReceivedAndRetiredForEmployeeTaxesPaid`	$14.00K	USD	2 Qtrs
Repayment of loan payable	`RepaymentsOfDebt`	$125.00K	USD	2 Qtrs
Repayment of loan payable	`RepaymentsOfDebt`	$750.00K	USD	2 Qtrs
Repayment of financing lease obligations	`FinanceLeasePrincipalPayments`	$84.00K	USD	2 Qtrs
Repayment of financing lease obligations	`FinanceLeasePrincipalPayments`	$35.00K	USD	2 Qtrs
Proceeds from PPP loan	`ProceedsFromIssuanceOfLongTermDebt`	$1.14M	USD	2 Qtrs
Proceeds from PPP loan	`ProceedsFromIssuanceOfLongTermDebt`	-	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$70.42M	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$19.28M	USD	2 Qtrs
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$39.33M	USD	2 Qtrs
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-5.28M	USD	2 Qtrs
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$23.77M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$18.50M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.84M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$48.17M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$23.77M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$18.50M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.84M	USD	Point-in-time
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$48.17M	USD	Point-in-time
Cash paid for interest	`InterestPaidNet`	$45.00K	USD	2 Qtrs
Cash paid for interest	`InterestPaidNet`	$70.00K	USD	2 Qtrs
Common stock issued for acquisition of Razor Genomics asset	`StockIssued1`	$5.76M	USD	2 Qtrs
Common stock issued for acquisition of Razor Genomics asset	`StockIssued1`	-	USD	2 Qtrs
Deferred tax liability generated from the acquisition of Razor Genomics asset	`DeferredTaxLiabilityGeneratedFromAcquisitionOfRazorGenomicsAsset`	-	USD	2 Qtrs
Deferred tax liability generated from the acquisition of Razor Genomics asset	`DeferredTaxLiabilityGeneratedFromAcquisitionOfRazorGenomicsAsset`	$7.56M	USD	2 Qtrs
Common stock issued for acquisition of Insight Genetics	`CommonStockIssuedForAcquisition`	-	USD	2 Qtrs
Common stock issued for acquisition of Insight Genetics	`CommonStockIssuedForAcquisition`	$5.00M	USD	2 Qtrs
Common stock issued for acquisition of Chronix Biomedical	`CommonStockIssuedForAcquisitionOfChronixBiomedical`	-	USD	2 Qtrs
Common stock issued for acquisition of Chronix Biomedical	`CommonStockIssuedForAcquisitionOfChronixBiomedical`	$3.30M	USD	2 Qtrs
Deferred tax liability generated from the acquisition of Chronix	`DeferredTaxLiabilityGeneratedFromAcquisitionOfChronix`	-	USD	2 Qtrs
Deferred tax liability generated from the acquisition of Chronix	`DeferredTaxLiabilityGeneratedFromAcquisitionOfChronix`	$1.79M	USD	2 Qtrs
Initial fair value of contingent consideration at acquisition date	`InitialFairValueOfContingentConsiderationAtAcquisitionDate`	$11.13M	USD	2 Qtrs
Initial fair value of contingent consideration at acquisition date	`InitialFairValueOfContingentConsiderationAtAcquisitionDate`	$42.30M	USD	2 Qtrs
Assumed liability from Chronix Acquisition	`AssumedLiabilityFromChronixAcquisition`	$9.29M	USD	2 Qtrs
Assumed liability from Chronix Acquisition	`AssumedLiabilityFromChronixAcquisition`	-	USD	2 Qtrs
Holdback liability	`HoldbackLiability`	$600.00K	USD	2 Qtrs
Holdback liability	`HoldbackLiability`	-	USD	2 Qtrs
Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability	`ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability`	$180.00K	USD	2 Qtrs
Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability	`ConstructionInProgressMachineryAndEquipmentPurchasesIncludedInAccountsPayableAccruedliabilitiesAndLandlordLiability`	$9.00K	USD	2 Qtrs

Stockholders Equity 37 line items

Line Item	Tag	Value	Unit	Period
Beginning balance, value	`StockholdersEquity`	$30.84M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$36.62M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$102.67M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$33.48M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$106.63M	USD	Point-in-time
Beginning balance, value	`StockholdersEquity`	$39.59M	USD	Point-in-time
Net Loss	`NetIncomeLoss`	$-16.84M	USD	2 Qtrs
Net Loss	`NetIncomeLoss`	$-10.49M	USD	1 Quarter
Net Loss	`NetIncomeLoss`	$-14.41M	USD	2 Qtrs
Net Loss	`NetIncomeLoss`	$-9.11M	USD	1 Quarter
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensationGross`	$3.29M	USD	2 Qtrs
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensationGross`	$2.30M	USD	2 Qtrs
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensationGross`	$2.00M	USD	1 Quarter
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensationGross`	$1.36M	USD	1 Quarter
Stock options exercised	`StockIssuedDuringPeriodValueStockOptionsExercised`	$1.25M	USD	1 Quarter
Stock options exercised	`StockIssuedDuringPeriodValueStockOptionsExercised`	$1.60M	USD	2 Qtrs
Warrants exercised	`StockIssuedDuringPeriodValueWarrantsExercised`	$21.00K	USD	1 Quarter
Warrants exercised	`StockIssuedDuringPeriodValueWarrantsExercised`	$823.00K	USD	2 Qtrs
Shares issued upon vesting of RSU, net of shares retired to pay employees taxes	`SharesIssuedUponVestingOfRsuNetOfSharesRetiredToPayEmployeesTaxes`	$-37.00K	USD	2 Qtrs
Shares issued upon vesting of RSU, net of shares retired to pay employees taxes	`SharesIssuedUponVestingOfRsuNetOfSharesRetiredToPayEmployeesTaxes`	$-14.00K	USD	2 Qtrs
Shares issued upon vesting of RSU, net of shares retired to pay employees taxes	`SharesIssuedUponVestingOfRsuNetOfSharesRetiredToPayEmployeesTaxes`	$-37.00K	USD	1 Quarter
Sale of common shares	`StockIssuedDuringPeriodValueNewIssues`	$10.75M	USD	1 Quarter
Sale of common shares	`StockIssuedDuringPeriodValueNewIssues`	$18.34M	USD	2 Qtrs
Issuance of common stock for Insight Genetics acquisition	`StockIssuedDuringPeriodValueAcquisitions`	$5.00M	USD	2 Qtrs
Issuance of common stock to Razor Genomics	`StockIssuedDuringPeriodValueAcquisitionsOne`	$5.76M	USD	2 Qtrs
Financing costs paid to issue common shares	`StockIssuedDuringPeriodValueOther`	$-31.00K	USD	2 Qtrs
Financing costs paid to issue common shares	`StockIssuedDuringPeriodValueOther`	$-31.00K	USD	1 Quarter
Issuance of common stock for Chronix Biomedical acquisition	`StockIssuedDuringPeriodValueAcquisitionsTwo`	$3.30M	USD	1 Quarter
Issuance of common stock for Chronix Biomedical acquisition	`StockIssuedDuringPeriodValueAcquisitionsTwo`	$3.30M	USD	2 Qtrs
Ending balance, value	`StockholdersEquity`	$30.84M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$36.62M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$102.67M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$33.48M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$106.63M	USD	Point-in-time
Ending balance, value	`StockholdersEquity`	$39.59M	USD	Point-in-time
Sale of common shares, including at-the-market transactions	`StockIssuedDuringPeriodValueOfSaleOfCommonSharesUnderAtthemarketTransactions`	$71.75M	USD	2 Qtrs
Financing costs paid to issue common shares, including at-the-market transactions	`StockIssuedDuringPeriodValueFinancingCostsPaidToIssueCommonSharesIncludingAtthemarketTransactions`	$-2.88M	USD	2 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.